Obe-Cel Displays Real-World Safety Benefits, Similar Efficacy to Brexu-Cel in R/R ALL

Obe-cel was associated with lower rates of CRS and ICANS vs brexu-cel in relapsed or refractory acute lymphoblastic leukemia.